Multimodal Assessment of Therapeutic Drug Resistance in OVCAR4 High Grade Serous Ovarian Carcinoma (HGSOC) Cells
DOI:
https://doi.org/10.47489/szmc.v40i2.899Keywords:
HGSOC, OVCAR4, CPZ, Metformin, Drug ResistanceAbstract
Background: Drug resistance is a major challenge for the treatment of high-grade serous ovarian carcinoma (HGSOC), frequently leading to disease recurrence and therapeutic failure.
Objective: This study investigated the cellular phenotypic and molecular bases of drug resistance in human ovarian cancer cell line such as OVCAR4.
Method: The chlorpromazine (CPZ) and metformin repurposed drugs were used for the treatment of ovarian cancer cells to follow the treatment response, and the hemocytometer and clonogenic assay were used, followed by the ANOVA and Tukey’s HSD post hoc test for statistical analysis. Surviving cell populations were recognized as drug resistant and further analysed at the molecular level. The OVCAR4 cells were used for RNA isolation and then converted into cDNA and used for real-time PCR, and PCR amplicons were verified by gel electrophoresis
Results: The molecular results were linked to the observable outcomes from the hemocytometer and clonogenic assay after drug treatment.
Conclusion: The research study provides a drug resistance-related inclusive analysis in ovarian cancer. Cellular and molecular analyses provide in vitro identification of resistance-associated markers and open a future path for therapeutic approaches to overcome drug resistance in ovarian cancer.
References
Ramraj SK, Elayapillai SP, Pelikan RC, Zhao YD, Isingizwe ZR, Kennedy AL, Lightfoot SA, Benbrook DM. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. Int J Cancer. 2020;147:1086-97. https://doi.org/10.1002/ijc.32830.
Holý P, Hlavá? V, Šeborová K, Š?sová S, Tesa?ová T, Rob L, Hruda M, Bouda J, Bartáková A, Mrhalová M, Kope?ková K, Al Obeed Allah M, Špa?ek J. Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression. Int J Cancer. 2024;155:104-16. https://doi.org/10.1002/ijc.34908.
Zhao R, Ning X, Lu H, Xu W, Ma J, Cheng J, Ma R. XTP8 Promotes Ovarian Cancer Progression by Activating AKT/AMPK/mTOR Pathway to Regulate EMT. Cell Biochem Biophys. 2024;82:945-57. https://doi.org/10.1007/s12013-024-01246-4.
Yuan Q, Lv N, Chen Q, Shen S, Wang Y, Tong J. Application of single cell sequencing technology in ovarian cancer research (review). Funct Integr Genomics. 2024;24:144. https://doi.org/10.1007/s10142-024-01432-w.
Xu J, Lu W, Wei X, Zhang B, Yang H, Tu M, Chen X, Wu S, Guo T. Single-cell transcriptomics reveals the aggressive landscape of high-grade serous carcinoma and therapeutic targets in tumor microenvironment. Cancer Lett. 2024;593:216928. https://doi.org/10.1016/j.canlet.2024.216928.
Giudice E, Huang TT, Nair JR, Zurcher G, McCoy A, Nousome D, Radke MR, Swisher EM, Lipkowitz S, Ibanez K, Donohue D, Malys T, Lee MJ, et al. The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial. Nat Commun. 2024;15:2805. https://doi.org/10.1038/s41467-024-47215-6.
Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun. 2013;4:2126. https://doi.org/10.1038/ncomms3126.
Beaufort CM, Helmijr JC, Piskorz AM, Hoogstraat M, Ruigrok-Ritstier K, Besselink N, Murtaza M, van ?cken WF, Heine AA, Smid M, Koudijs MJ, Brenton JD, Berns EM, Helleman J. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One. 2014;9(9):e103988. https://doi.org/10.1371/journal.pone.0103988.
Zhong F, Zhu T, Pan X, Zhang Y, Yang H, Wang X, Hu J, Han H, Mei L, Chen D, Wang K, Zhou X, Li X, Dong Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53. Cancer Med. 2019;8:3928-35. https://doi.org/10.1002/cam4.2243.
Bradbury A, O’Donnell R, Drew Y, Curtin NJ, Sharma Saha S. Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic Targeting. Cancers. 2020;12(7):1939. https://doi.org/10.3390/cancers12071939.
Ereku LT, Mackay RE, Craw P, Naveenathayalan A, Stead Branavan M, Balachandran W. RPA using a multiplexed cartridge for low cost point of care diagnostics in the field. Anal Biochem. 2018;547:84-88. https://doi.org/10.1016/j.ab.2018.02.010.
Iqbal F, Asif MS, Qureshi AG, Shah JA, Abdikaxarovich SA, Adil MN, Hussain A. RPA-Based colorimetric detection of SARS-Cov-2 (Covid-19) and its physiological effects. Int J Health Sci. 2023;6 (S7):6804-6818. https://doi.org/10.53730/ijhs.v6nS7.13862.
Naveed AM, Royaidar J, Wadie YRR, GonzagaLeong-on MS, Iqbal F, Hussain A, Ali Q, Rasheed A. Epidemiology and Resistance Pattern in Microbial Pneumonia: A Review. Pak J Health Sci. 2022;3:27-31. https://doi.org/10.54393/pjhs.v3i05.229.
Iqbal F. Enhancing the effectiveness of Chimeric Antigen Receptor (CAR) T cells against tumors through CRISPR/Cas9-mediated PD-1 disruption. Int J Health Sci. 2023;7:1836-50. https://doi.org/10.53730/ijhs.v7nS1.14397.
Iqbal F. CRISPR/Cas9-based manipulation of oncogenic chromosomal changes in vivo and drug impact on blood pressure. Int J Health Sci. 2023;7:2130-39. https://doi.org/10.53730/ijhs.v7nS1.14461.
Gockley A, Melamed A, Bregar AJ, Clemmer JT, Birrer M, Schorge JO, Del Carmen MG, Rauh-Hain JA. Outcomes of Women with High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer. Obstet Gynecol. 2017;129:439-47. https://doi.org/10.1097/AOG.0000000000001867.
Garziera M, Cecchin E, Canzonieri V, Sorio R, Giorda G, Scalone S, De Mattia E, Roncato R, Gagno S, Poletto E, Romanato L, Sartor F, Polesel J, Toffoli G. Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS). Int J Mol Sci. 2018;19(5):1510. https://doi.org/10.3390/ijms19051510.
Iqbal F. Bridging clinical insight and laboratory model in high-grade serous ovarian carcinoma (HGSOC) using DNA sequencing-based profiling of TP53. Oncoscience. 2025;12:168-174. https://doi.org/10.18632/oncoscience.632.
Iqbal F. Pharmacological Reinvention: Drug Repurposing Strategies to Tackle Aggressive High Grade Serous Ovarian Carcinoma (HGSOC). J Cancer Sci Clin Ther. 2025;9:189-198. https://doi.org/10.26502/jcsct.5079276.
Iqbal F. Developing Synergistic Therapeutic Strategy to Uncover Enhanced Anti-Tumor Efficacy in High-Grade Serous Ovarian Carcinoma (HGSOC). Int J Pharm Integr Health Sci. 2026;7:19-28. https://doi.org/10.56536/ijpihs.v7i1.284.
Iqbal F. A low-cost color sensor device for rapid detection of high-grade serous ovarian carcinoma (HGSOC). Oncoscience. 2026 Mar 11;13:104-114. https://doi.org/10.18632/oncoscience.652.
This work is licensed under a 